LLY News Explorer

Investors are weighing what a reported gradual rollout of Trump tariff hikes could mean for inflation and the Fed.

(Bloomberg) -- Stocks and bonds saw small moves, with Wall Street traders unwilling to make any significant bets as they await key inflation data for clues on path of Federal Reserve rates over the next few months.Most Read from BloombergThese Homes Withstood the LA Fires. Architects Explain WhyA Blueprint for Better Bike LanesAs E-Bikes Boom in NYC, Some Call for More RegulationsIn the run-up to Wednesday’s consumer price index, the S&P 500 was little changed after an earlier advance that came

The FDA decided the shortage for Eli Lilly's GLP-1 tirzepatide has finally come to an end.

The excitement around the new weight-loss industry is overtaking other disease areas and portfolios for publicly traded companies.

Eli Lilly is set to report Q3 earnings Wednesday, as the pharma giant continues to gain market share in the weight loss drug space.

Eli Lilly is set to report Q3 earnings Wednesday, as the pharma giant continues to gain market share in the weight loss drug space.

GLP-1 pills are the next frontier for the weight-loss market.

Investor's Business Daily executive editor Alissa Coram discusses whether the 'down' stock market is due for a bounce this week on 'Varney & Co.'

The telehealth world is entering a new phase of vertical integration in healthcare.

Eli Lilly is trying to reduce shortages of its Zepbound weight loss GLP-1 by launching vials and lowering prices for out-of-pocket payers.

Eli Lilly is launching more supply of its weight loss drug Zepbound. The new single-dose vials will be priced lower than "all other incretin GLP-1 medicines for obesity."